Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene therapy Elevidys in the wake of the death of a patient who received the ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

A high-level overview of Sarepta Therapeutics, Inc. (SRPT) stock. View (SRPT) real-time stock price, chart, news, analysis, analyst reviews and more.

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the middle ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

Roche, Sarepta Therapeutics sign $1.15B deal for ex-US rights to gene therapy for Duchenne’s An analyst wrote that the deal would create value for Sarepta, ...

Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for about $1.3 billion. Two of the one-time treatments are in the clinic. Lead candidate VERVE-102, a gene-editing ...